Physician profile
Freidoon Ghazi
NPI 1922098342
$55,697.86
in general payments reported to CMS, 2019-2025
36 companies · $7,043 in 2025
The $7,043 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $16K · 2021: $4,262 · 2022: $1,681 · 2023: $1,304 · 2024: $1,256 · 2025: $7,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,917 · Food and Beverage: $4,086 · Travel and Lodging: $521 · Education: $78.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,917.00 |
| Food and Beverage | $4,086.37 |
| Travel and Lodging | $520.63 |
| Education | $78.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $21,311.79 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $15,502.01 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Bayer Healthcare Pharmaceuticals INC. | $5,988.81 | 2022-2025 | |
| Boston Scientific Corporation | $5,875.31 | 2019-2025 | Accolade Sr, Mylux Patient Kit With Mobile Device, Resonate El Icd Vr |
| Novartis Pharmaceuticals Corporation | $2,291.43 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $643.18 | 2019-2025 | Jardiance |
| Abbott Laboratories | $579.93 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip, Cardiomems |
| Amarin Pharma, INC. | $572.53 | 2019-2023 | |
| Amgen INC. | $304.36 | 2019-2025 | Repatha |
| Merck Sharp & Dohme LLC | $292.75 | 2022 | |
| Pfizer INC. | $281.88 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $245.38 | 2024-2025 | Uptravi, Opsumit |
| Daiichi Sankyo INC. | $179.96 | 2021-2025 | Injectafer |
| Alnylam Pharmaceuticals INC. | $167.80 | 2024-2025 | Amvuttra, Onpattro |
| Edwards Lifesciences Corporation | $167.23 | 2020-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $163.64 | 2022 | |
| Zoll Respicardia, INC. | $138.11 | 2025 | Remede System |
| E.R. Squibb & Sons, L.L.C. | $132.20 | 2022 | |
| Ani Pharmaceuticals, INC. | $125.00 | 2024 | Purified Cortrophin Gel |
| Abiomed | $124.99 | 2019 | |
| Esperion Therapeutics, INC. | $110.58 | 2021 | |
| Lilly USA, LLC | $94.38 | 2019 | |
| Scpharmaceuticals INC. | $63.35 | 2024 | |
| Irhythm Technologies, INC. | $59.50 | 2023 | Zio Xt Patch |
| Novo Nordisk INC | $52.76 | 2022-2023 | Ozempic |
| Vifor Pharma, INC. | $35.96 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.91 | 2021-2023 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $28.30 | 2023-2024 | Inpefa |
| Inari Medical, INC. | $25.37 | 2022 | |
| Cook Medical LLC | $24.21 | 2021 | |
| Lantheus Medical Imaging, INC. | $23.25 | 2024 | |
| Sanofi-Aventis U.S. LLC | $17.48 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.48 | 2022 | |
| Terumo Medical Corporation | $12.61 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.43 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Freidoon Ghazi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.